Skip to main content

Table 1 Patient demographics and baseline clinical data

From: Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension

Variables PAH (n = 42) Healthy Controls (n = 11) p-value
Age (years), median (range) 71 (63–79) 66 (60–69) 0.123
Females sex, n (%) 27 (68%) 4 (36%) 0.061
Comorbidities
 Hypertension, n (%) 22 (52%) 0  
 Diabetes, n (%) 7 (17%) 0  
 Dyslipidaemia, n(%) 13 (31%) 0  
 Chronic Obstructive Airways Disease, n (%) 10 (24%) 0  
 Obstructive Sleep Apnoea, n (%) 11 (26%) 0  
 Atrial Fibrillation, n (%) 8 (19%) 0  
Right heart catheter haemodynamic indices
 Mean pulmonary artery pressures (mmHg), median (range) 33 (16–57) 0  
 Pulmonary artery wedge pressure (mmHg), median (range) 12 (4–15) 0  
 Mean right atrial pressures (mmHg), median (range) 12 (2–18) 0  
 Cardiac index (L/min/m2), median (range) 3 (2–4) 0  
Pulmonary vascular resistance index (Woods unit m2), median (range) 7 (3–28) 0  
Medication
 Aspirin, n (%) 6 (14%) 0  
 Beta-blockers, n (%) 10 (24%) 0  
 ACEi/ARB, n (%) 12 (29%) 0  
 Statins, n (%) 8 (19%) 0  
 Calcium channel blockers 13 (31%) 0  
 Endothelin receptor blockers, n (%) 34 (81%) 0  
 PDE5 inhibitor, n (%) 18 (43%) 0  
 Soluble guanylate cyclase, n (%) 3 (7%) 0  
 Combination therapy, n (%)a 14 (33%) 0  
  1. aCombination therapy of a dual therapy compromising of either endothelin receptor blocker, PDE5 inhibitor or soluble guanylate cyclase
  2. ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, PDE5 phosphodiesterase type 5 inhibitor